Related Experiment Video
Updated: Oct 30, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
Alicia González1, Carolina Alonso-González1, Alicia González-González1
1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Instituto de Investigación Valdecilla (IDIVAL), 39011 Santander, Spain.
Abstract:
Melatonin is a hormone with different functions, antitumor actions being one of the most studied. Among its antitumor mechanisms is its ability to inhibit angiogenesis. Melatonin shows antiangiogenic effects in several types of tumors. Combination of melatonin and chemotherapeutic agents have a synergistic effect inhibiting angiogenesis. One of the undesirable effects of chemotherapy is the induction of pro-angiogenic factors, whilst the addition of melatonin is able to overcome these undesirable effects. This protective effect of the pineal hormone against angiogenesis might be one of the mechanisms underlying its anticancer effect, explaining, at least in part, why melatonin administration increases the sensitivity of tumors to the inhibitory effects exerted by ordinary chemotherapeutic agents. Melatonin has the ability to turn cancer totally resistant to chemotherapeutic agents into a more sensitive chemotherapy state. Definitely, melatonin regulates the expression and/or activity of many factors involved in angiogenesis which levels are affected (either positively or negatively) by chemotherapeutic agents. In addition, the pineal hormone has been proposed as a radiosensitizer, increasing the oncostatic effects of radiation on tumor cells. This review serves as a synopsis of the interaction between melatonin and angiogenesis, and we will outline some antiangiogenic mechanisms through which melatonin sensitizes cancer cells to treatments, such as radiotherapy or chemotherapy.
Insights
Melatonin, a hormone, inhibits tumor angiogenesis and enhances chemotherapy sensitivity. It counteracts chemotherapy-induced pro-angiogenic factors, acting as a potential radiosensitizer.
Area of Science:
- Oncology
- Endocrinology
- Cancer Biology
Background:
- Melatonin is a hormone with studied antitumor properties.
- Inhibition of angiogenesis is a key antitumor mechanism of melatonin.
- Melatonin's interaction with chemotherapy and radiotherapy is under investigation.
Purpose of the Study:
- To review the interaction between melatonin and angiogenesis.
- To outline mechanisms by which melatonin sensitizes cancer cells to treatment.
- To explore melatonin's role in overcoming chemotherapy resistance.
Main Methods:
- Literature review on melatonin's antiangiogenic and radiosensitizing effects.
- Analysis of melatonin's impact on factors regulating angiogenesis.
- Examination of synergistic effects of melatonin with chemotherapy and radiotherapy.
Main Results:
- Melatonin exhibits antiangiogenic effects across various tumor types.
- Combination therapy with melatonin and chemotherapy shows synergistic antiangiogenic effects.
- Melatonin counteracts chemotherapy-induced pro-angiogenic factors and enhances tumor cell sensitivity to chemotherapy and radiotherapy.
Conclusions:
- Melatonin's antiangiogenic properties contribute to its anticancer effects.
- Melatonin can overcome cancer resistance to chemotherapy.
- Melatonin acts as a radiosensitizer, enhancing the efficacy of cancer treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
The Tumor Microenvironment
Tumor Immunotherapy
Management of Insomnia

